The first-in-class humanized IgG4 mAb IPH2101, targeting an epitope shared by KIR2D, was produced to block the binding of HLA-C to KIR2D to release NK cell inhibition and enhance NK cells' capacity to kill tumor targets. The gene discussed is HLA-C; the disease is neoplasm.